1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Nerve Blocks Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Nerve Blocks Market, by Product Type
8.1.1. Single-Injection Nerve Blocks
8.1.1.1. Market Revenue and Forecast
8.1.2. Continuous Nerve Blocks
8.1.2.1. Market Revenue and Forecast
9.1. Nerve Blocks Market, by Drug/Agent Type
9.1.1. Bupivacaine-based Blocks
9.1.1.1. Market Revenue and Forecast
9.1.2. Ropivacaine-based Blocks
9.1.2.1. Market Revenue and Forecast
9.1.3. Lidocaine-based Blocks
9.1.3.1. Market Revenue and Forecast
9.1.4. Other Local Anesthetics
9.1.4.1. Market Revenue and Forecast
10.1. Nerve Blocks Market, by Application
10.1.1. Surgical Procedures
10.1.1.1. Market Revenue and Forecast
10.1.2. Pain Management (Chronic & Acute)
10.1.2.1. Market Revenue and Forecast
10.1.3. Obstetrics & Gynecology
10.1.3.1. Market Revenue and Forecast
10.1.4. Dental & Others
10.1.4.1. Market Revenue and Forecast
11.1. Nerve Blocks Market, by End User
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Ambulatory Surgical Centers (ASCs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Specialty Clinics
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Forecast
12.1. Nerve Blocks Market, by Technique
12.1.1. Ultrasound-Guided Nerve Blocks
12.1.1.1. Market Revenue and Forecast
12.1.2. Nerve Stimulator-Guided Blocks
12.1.2.1. Market Revenue and Forecast
12.1.3. Landmark-Based Techniques
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type
13.1.2. Market Revenue and Forecast, by Drug/Agent Type
13.1.3. Market Revenue and Forecast, by Application
13.1.4. Market Revenue and Forecast, by End User
13.1.5. Market Revenue and Forecast, by Technique
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type
13.1.6.2. Market Revenue and Forecast, by Drug/Agent Type
13.1.6.3. Market Revenue and Forecast, by Application
13.1.6.4. Market Revenue and Forecast, by End User
13.1.6.5. Market Revenue and Forecast, by Technique
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type
13.1.7.2. Market Revenue and Forecast, by Drug/Agent Type
13.1.7.3. Market Revenue and Forecast, by Application
13.1.7.4. Market Revenue and Forecast, by End User
13.1.7.5. Market Revenue and Forecast, by Technique
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type
13.2.2. Market Revenue and Forecast, by Drug/Agent Type
13.2.3. Market Revenue and Forecast, by Application
13.2.4. Market Revenue and Forecast, by End User
13.2.5. Market Revenue and Forecast, by Technique
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type
13.2.6.2. Market Revenue and Forecast, by Drug/Agent Type
13.2.6.3. Market Revenue and Forecast, by Application
13.2.7. Market Revenue and Forecast, by End User
13.2.8. Market Revenue and Forecast, by Technique
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type
13.2.9.2. Market Revenue and Forecast, by Drug/Agent Type
13.2.9.3. Market Revenue and Forecast, by Application
13.2.10. Market Revenue and Forecast, by End User
13.2.11. Market Revenue and Forecast, by Technique
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type
13.2.12.2. Market Revenue and Forecast, by Drug/Agent Type
13.2.12.3. Market Revenue and Forecast, by Application
13.2.12.4. Market Revenue and Forecast, by End User
13.2.13. Market Revenue and Forecast, by Technique
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type
13.2.14.2. Market Revenue and Forecast, by Drug/Agent Type
13.2.14.3. Market Revenue and Forecast, by Application
13.2.14.4. Market Revenue and Forecast, by End User
13.2.15. Market Revenue and Forecast, by Technique
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type
13.3.2. Market Revenue and Forecast, by Drug/Agent Type
13.3.3. Market Revenue and Forecast, by Application
13.3.4. Market Revenue and Forecast, by End User
13.3.5. Market Revenue and Forecast, by Technique
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type
13.3.6.2. Market Revenue and Forecast, by Drug/Agent Type
13.3.6.3. Market Revenue and Forecast, by Application
13.3.6.4. Market Revenue and Forecast, by End User
13.3.7. Market Revenue and Forecast, by Technique
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type
13.3.8.2. Market Revenue and Forecast, by Drug/Agent Type
13.3.8.3. Market Revenue and Forecast, by Application
13.3.8.4. Market Revenue and Forecast, by End User
13.3.9. Market Revenue and Forecast, by Technique
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type
13.3.10.2. Market Revenue and Forecast, by Drug/Agent Type
13.3.10.3. Market Revenue and Forecast, by Application
13.3.10.4. Market Revenue and Forecast, by End User
13.3.10.5. Market Revenue and Forecast, by Technique
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type
13.3.11.2. Market Revenue and Forecast, by Drug/Agent Type
13.3.11.3. Market Revenue and Forecast, by Application
13.3.11.4. Market Revenue and Forecast, by End User
13.3.11.5. Market Revenue and Forecast, by Technique
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type
13.4.2. Market Revenue and Forecast, by Drug/Agent Type
13.4.3. Market Revenue and Forecast, by Application
13.4.4. Market Revenue and Forecast, by End User
13.4.5. Market Revenue and Forecast, by Technique
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type
13.4.6.2. Market Revenue and Forecast, by Drug/Agent Type
13.4.6.3. Market Revenue and Forecast, by Application
13.4.6.4. Market Revenue and Forecast, by End User
13.4.7. Market Revenue and Forecast, by Technique
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type
13.4.8.2. Market Revenue and Forecast, by Drug/Agent Type
13.4.8.3. Market Revenue and Forecast, by Application
13.4.8.4. Market Revenue and Forecast, by End User
13.4.9. Market Revenue and Forecast, by Technique
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type
13.4.10.2. Market Revenue and Forecast, by Drug/Agent Type
13.4.10.3. Market Revenue and Forecast, by Application
13.4.10.4. Market Revenue and Forecast, by End User
13.4.10.5. Market Revenue and Forecast, by Technique
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type
13.4.11.2. Market Revenue and Forecast, by Drug/Agent Type
13.4.11.3. Market Revenue and Forecast, by Application
13.4.11.4. Market Revenue and Forecast, by End User
13.4.11.5. Market Revenue and Forecast, by Technique
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type
13.5.2. Market Revenue and Forecast, by Drug/Agent Type
13.5.3. Market Revenue and Forecast, by Application
13.5.4. Market Revenue and Forecast, by End User
13.5.5. Market Revenue and Forecast, by Technique
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type
13.5.6.2. Market Revenue and Forecast, by Drug/Agent Type
13.5.6.3. Market Revenue and Forecast, by Application
13.5.6.4. Market Revenue and Forecast, by End User
13.5.7. Market Revenue and Forecast, by Technique
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type
13.5.8.2. Market Revenue and Forecast, by Drug/Agent Type
13.5.8.3. Market Revenue and Forecast, by Application
13.5.8.4. Market Revenue and Forecast, by End User
13.5.8.5. Market Revenue and Forecast, by Technique
14.1. B. Braun Melsungen AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Fresenius Kabi AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Novartis AG
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. GlaxoSmithKline plc
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Merck & Co., Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. AbbVie Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Mylan N.V.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. AstraZeneca plc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Abbott
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
